[Use of immunomocorrection in the combined treatment of laryngeal papillomatosis in children].

Savenko IV, Tsvetkov EA

Vestnik otorinolaringologii1 Jul 1996

PMID8966869PepBankPUB-08966869

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In children with laryngeal papillomatosis, a combined regimen including thymalin increased remission duration 1.6--2.6-fold.
In plain wordsIn children with laryngeal papillomatosis, a combined regimen including thymalin increased remission duration.
Peptide
Thymalin
Outcome
IncreaseRemission duration
Study
n = 39
Outcome group
Overall treatment effect · Respiratory
Measurements
Remission duration increase
1.6 to 2.6 fold
combined treatment
Source sentences
Summary
Remission duration increased 1.6--2.6-fold, 6 of 7 children with primary LP achieved persistent remission.
3 context sentences(design, population, supporting numbers)
Summary · context
Such treatment was given to 39 children.
Summary · context
Original immunological studies allowed the authors to design a combined treatment of laryngeal papillomatosis (LP) with administration of immunomodulators and cytostatics.
Summary · context
Thymic hormone preparation (T-activin, thymalin, thymogen) and prospidin served as immunomodulators and cytostatic, respectively.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0896686901
02HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In children with laryngeal papillomatosis, a combined regimen including thymalin produced positive immunological changes in 84%.
In plain wordsIn children with laryngeal papillomatosis, a combined regimen including thymalin produced positive immune changes in 84%.
Peptide
Thymalin
Outcome
Direction not reportedPositive immunological changes
Study
n = 39
Outcome group
Immune response · Immune and inflammation
Measurements
Positive immunological changes
84%
children
Source sentences
Summary
Positive changes in immunological indices occurred in 84% of children.
3 context sentences(design, population, supporting numbers)
Summary · context
Such treatment was given to 39 children.
Summary · context
Original immunological studies allowed the authors to design a combined treatment of laryngeal papillomatosis (LP) with administration of immunomodulators and cytostatics.
Summary · context
Thymic hormone preparation (T-activin, thymalin, thymogen) and prospidin served as immunomodulators and cytostatic, respectively.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0896686903
03HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
With a combined regimen including thymalin, 6 of 7 children with primary laryngeal papillomatosis achieved persistent remission.
In plain wordsWith a combined regimen including thymalin, 6 of 7 children with primary laryngeal papillomatosis achieved persistent remission.
Peptide
Thymalin
Outcome
Not applicablePersistent remission in primary papillomatosis
Study
n = 7
Outcome group
Overall treatment effect · Respiratory
Measurements
Persistent remission
6 children
primary LP
Source sentences
Summary
Remission duration increased 1.6--2.6-fold, 6 of 7 children with primary LP achieved persistent remission.
2 context sentences(design, population, supporting numbers)
Summary · context
Original immunological studies allowed the authors to design a combined treatment of laryngeal papillomatosis (LP) with administration of immunomodulators and cytostatics.
Summary · context
Thymic hormone preparation (T-activin, thymalin, thymogen) and prospidin served as immunomodulators and cytostatic, respectively.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0896686902
04HumanNot a test of Thymogen (oglufanide) aloneCase report or seriesEfficacy outcome
In children with laryngeal papillomatosis, the combined regimen including thymic preparations increased remission duration 1.6--2.6-fold.
In plain wordsIn children with laryngeal papillomatosis, combined treatment including thymic preparations increased remission duration 1.6--2.6-fold.
Peptide
Thymogen (oglufanide)
Outcome
IncreaseRemission duration
Study
n = 39
Children with laryngeal papillomatosis
Outcome group
Infection and antimicrobial activity · Respiratory
Measurements
Remission duration increase
1.6 to 2.6 fold
combined treatment
Source sentences
Summary
Remission duration increased 1.6--2.6-fold, 6 of 7 children with primary LP achieved persistent remission.
3 context sentences(design, population, supporting numbers)
Summary · context
Original immunological studies allowed the authors to design a combined treatment of laryngeal papillomatosis (LP) with administration of immunomodulators and cytostatics.
Summary · context
Thymic hormone preparation (T-activin, thymalin, thymogen) and prospidin served as immunomodulators and cytostatic, respectively.
Summary · context
Such treatment was given to 39 children.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-0896686904
05HumanNot a test of Thymogen (oglufanide) aloneCase report or seriesEfficacy outcome
In children with laryngeal papillomatosis, positive immunological changes occurred in 84% during the combined regimen.
In plain wordsIn children with laryngeal papillomatosis, 84% showed positive immune changes during combined treatment.
Peptide
Thymogen (oglufanide)
Outcome
IncreasePositive immunological changes
Study
n = 39
Children with laryngeal papillomatosis
Outcome group
Immune response · Immune and inflammation
Measurements
Positive immunological changes
84%
children receiving combined treatment
Source sentences
Summary
Positive changes in immunological indices occurred in 84% of children.
3 context sentences(design, population, supporting numbers)
Summary · context
Original immunological studies allowed the authors to design a combined treatment of laryngeal papillomatosis (LP) with administration of immunomodulators and cytostatics.
Summary · context
Thymic hormone preparation (T-activin, thymalin, thymogen) and prospidin served as immunomodulators and cytostatic, respectively.
Summary · context
Such treatment was given to 39 children.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-0896686906
06HumanNot a test of Thymogen (oglufanide) aloneCase report or seriesEfficacy outcome
With the combined regimen, 6 of 7 children with primary laryngeal papillomatosis achieved persistent remission.
In plain wordsWith combined treatment, 6 of 7 children with primary laryngeal papillomatosis achieved persistent remission.
Peptide
Thymogen (oglufanide)
Outcome
Not applicablePersistent remission in primary laryngeal papillomatosis
Study
n = 7
Children with laryngeal papillomatosis
Outcome group
Infection and antimicrobial activity · Respiratory
Measurements
Persistent remission
6 children
7 children with primary disease
Source sentences
Summary
Remission duration increased 1.6--2.6-fold, 6 of 7 children with primary LP achieved persistent remission.
3 context sentences(design, population, supporting numbers)
Summary · context
Original immunological studies allowed the authors to design a combined treatment of laryngeal papillomatosis (LP) with administration of immunomodulators and cytostatics.
Summary · context
Thymic hormone preparation (T-activin, thymalin, thymogen) and prospidin served as immunomodulators and cytostatic, respectively.
Summary · context
Such treatment was given to 39 children.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-0896686905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 12:50 UTC
Study data updated · source update from Europe PMC
Version 2
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.